Literature DB >> 8669461

Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques.

R Prior1, D D'Urso, R Frank, I Prikulis, S Cleven, R Ihl, G Pavlakovic.   

Abstract

Alzheimer's disease is characterized by the progressive accumulation of amyloid-beta protein (Abeta) in senile plaques and cerebral amyloid angiopathy. It is not known whether the plaque growth is a continuous and homogeneous process or whether some plaques have a more rapid evolution. As plaques grow by the deposition of Abeta, we used an in situ binding technique to analyze the deposition of fluorescein-conjugated and biotinylated Abeta1 40 and Abeta1-42 in cryosections of brains from Alzheimer's disease patients. Only a subset of senile plaques but all cerebrovascular Abeta deposits were labeled by both Abeta1-40 and Abeta1-42. Striking differences in binding were observed among adjacent plaques. Quantitative analysis showed that on average 60% of all plaques were labeled with Abeta1-42 and 31% of all plaques were labeled with Abeta1-40 (n=7; P<0.001). Confocal laser scanning microscopy of double-labeled sections revealed that the newly deposited Abeta was only partially co-localized to pre-existing Abeta and apolipoprotein E and was not co-localized to heparan sulfate proteoglycan. Abeta binding was preserved after glycolytic pretreatment with periodic acid. Our results suggest that at a given time point only a subset of active senile plaques accumulate A(beta) and that plaque growth may be conditioned by the presence of other distinct plaque components different from Abeta, apolipoprotein E or heparan sulfate proteoglycan.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8669461      PMCID: PMC1861649     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Differences between vascular and plaque core amyloid in Alzheimer's disease.

Authors:  F Prelli; E Castaño; G G Glenner; B Frangione
Journal:  J Neurochem       Date:  1988-08       Impact factor: 5.372

2.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.

Authors:  J Kang; H G Lemaire; A Unterbeck; J M Salbaum; C L Masters; K H Grzeschik; G Multhaup; K Beyreuther; B Müller-Hill
Journal:  Nature       Date:  1987 Feb 19-25       Impact factor: 49.962

Review 3.  Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease.

Authors:  D J Selkoe
Journal:  Annu Rev Cell Biol       Date:  1994

4.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

Authors:  T Iwatsubo; A Odaka; N Suzuki; H Mizusawa; N Nukina; Y Ihara
Journal:  Neuron       Date:  1994-07       Impact factor: 17.173

5.  Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide.

Authors:  J E Maggio; E R Stimson; J R Ghilardi; C J Allen; C E Dahl; D C Whitcomb; S R Vigna; H V Vinters; M E Labenski; P W Mantyh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

6.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

Authors:  S A Gravina; L Ho; C B Eckman; K E Long; L Otvos; L H Younkin; N Suzuki; S G Younkin
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

7.  Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis.

Authors:  P L Richey; S L Siedlak; M A Smith; G Perry
Journal:  Biochem Biophys Res Commun       Date:  1995-03-17       Impact factor: 3.575

8.  Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

Authors:  P Seubert; C Vigo-Pelfrey; F Esch; M Lee; H Dovey; D Davis; S Sinha; M Schlossmacher; J Whaley; C Swindlehurst
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

9.  Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.

Authors:  D Burdick; B Soreghan; M Kwon; J Kosmoski; M Knauer; A Henschen; J Yates; C Cotman; C Glabe
Journal:  J Biol Chem       Date:  1992-01-05       Impact factor: 5.157

10.  The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease.

Authors:  A D Snow; H Mar; D Nochlin; K Kimata; M Kato; S Suzuki; J Hassell; T N Wight
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

View more
  7 in total

1.  Probing the efficacy of peptide-based inhibitors against acid- and zinc-promoted oligomerization of amyloid-β peptide via single-oligomer spectroscopy.

Authors:  Lyndsey R Powell; Kyle D Dukes; Robin K Lammi
Journal:  Biophys Chem       Date:  2011-09-08       Impact factor: 2.352

2.  Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.

Authors:  D Wu; J Yang; W M Pardridge
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Variable deposition of amyloid beta-protein (A beta) with the carboxy-terminus that ends at residue valine40 (A beta 40) in the cerebral cortex of patients with Alzheimer's disease: a double-labeling immunohistochemical study with antibodies specific for A beta 40 and the A beta that ends at residues alanine42/threonine43 (A beta 42).

Authors:  H Akiyama; H Mori; N Sahara; H Kondo; K Ikeda; T Nishimura; T Oda; P L McGeer
Journal:  Neurochem Res       Date:  1997-12       Impact factor: 3.996

4.  Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.

Authors:  J B Mackic; M Stins; J G McComb; M Calero; J Ghiso; K S Kim; S D Yan; D Stern; A M Schmidt; B Frangione; B V Zlokovic
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

5.  Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.

Authors:  Ming-Jang Chiu; Shieh-Yueh Yang; Herng-Er Horng; Che-Chuan Yang; Ta-Fu Chen; Jen-Je Chieh; Hsin-Hsien Chen; Ting-Chi Chen; Chia-Shin Ho; Shuo-Fen Chang; Hao Chun Liu; Chin-Yih Hong; Hong-Chang Yang
Journal:  ACS Chem Neurosci       Date:  2013-10-23       Impact factor: 4.418

6.  Reversibility of beta-amyloid self-assembly: effects of pH and added salts assessed by fluorescence photobleaching recovery.

Authors:  Nadia J Edwin; Robert P Hammer; Robin L McCarley; Paul S Russo
Journal:  Biomacromolecules       Date:  2010-02-08       Impact factor: 6.988

7.  Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice.

Authors:  Rachel A Karlnoski; Arnon Rosenthal; Dione Kobayashi; Jaume Pons; Jennifer Alamed; Mary Mercer; Qingyou Li; Marcia N Gordon; Paul E Gottschall; David Morgan
Journal:  J Neurosci       Date:  2009-04-15       Impact factor: 6.167

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.